SFB 1530 on B-Cell Neoplasms Extended

The spokesperson for the Collaborative Research Center is Prof. Michael Hallek, MD, PhD, Director of Department I for Internal Medicine and the Center for Integrated Oncology at the University Hospital of Cologne as well as Executive Board Member at the Center for Molecular Medicine Cologne (CMMC). He emphasizes: “The extension of our Collaborative Research Center is a recognition of the outstanding work of our scientists and our partners from Cologne, Berlin, Frankfurt, Duisburg, and Essen. For the second funding phase, we are highly motivated to further improve the treatment of patients with lymph node cancer through our research.”

The SFB 1530 brings together the expertise of researchers in lymphoma and inflammation research at the University of Cologne and the University Hospital of Cologne. The goal of this interdisciplinary consortium is to unravel new mechanisms underlying the development of lymphomas and to develop innovative therapeutic approaches for patients with forms of lymphoma that have a poor prognosis. The focus is on the targeted disruption of cancer-triggering signaling pathways and the modulation of the tumor microenvironment.
 

This message has been translated and modified by the CMMC (K. Heber & D. Grosskopf-Kroiher) and is based on the text by the press and communications teams of the University Hospoital Cologne (original German version here).